NCT02313103View on ClinicalTrials.gov

Single-dose Pharmacokinetics and Safety of Oral Lofexidine in Renally-Impaired Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
Renally Impaired Subjects
Interventions
DRUG

lofexidine HCl

400 micrograms

Trial Locations (1)

Unknown

Orlando

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

USWM, LLC (dba US WorldMeds)

INDUSTRY

NCT02313103 - Single-dose Pharmacokinetics and Safety of Oral Lofexidine in Renally-Impaired Subjects | Biotech Hunter | Biotech Hunter